Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Eli Lilly shares slipped after hitting new highs, even as the company’s weight-loss and diabetes franchise tied to Mounjaro and Zepbound continued to drive unusually strong demand.
THE APEX TIMES
THE APEX TIMES
A new market commentary points to Eli Lilly’s pipeline as the next leg of growth after the company’s rare valuation milestone, arguing investors may be discounting how the next two years could unfold.
THE APEX TIMES
A clinical-stage radiopharmaceutical startup with no product revenue has drawn interest from three of pharma’s biggest acquirers. Analysts point to the kind of rights structure embedded in a Lilly partnership as a key driver of why large drugmakers would move.
THE APEX TIMES
A public market fight over obesity treatments is expanding beyond injections, as Eli Lilly and Novo Nordisk compete to capture demand for oral weight-loss drugs and defend their broader positions in the obesity market.
THE APEX TIMES
A new comparison of UnitedHealth Group and Eli Lilly highlights that both companies maintain dividend programs with long-running appeal, while their dividend maturity levels appear to differ.
THE APEX TIMES
Eli Lilly’s stock gained in the afternoon session after the company disclosed two separate transactions, including rights to a preclinical Alzheimer’s drug and a new research collaboration, according to a market report.
THE APEX TIMES
The pharmaceutical company announced new research partnerships spanning ion channel drug discovery and a trial collaboration in KRAS G12C-mutant lung cancer, indicating continued investment in both neuroscience and precision oncology.
THE APEX TIMES
The move comes as traders weigh demand momentum behind Mounjaro and Zepbound, while a separate valuation snapshot suggests the stock may trade below an estimated fair value.
THE APEX TIMES
Eli Lilly was named “Stock of the Day,” with market commentary arguing it is catching up after an earlier advantage for Novo Nordisk in weight-loss drug performance. The post also flagged two possible share-price entry points, reflecting a still-volatility-prone setup.
